Disappointing Q1 earnings call, and not very impressed with management and their execution. They had a chance to increase revenue guidance, but did not do so. What does this mean? I expect to see much higher sales beyond estimates for Q2. They seem to be playing it very conservatively, with revenue projections not including increased sales from Venofer supply issue (which they would see in April of Q2) and not including $33M in possible milestones from Takeda upon EU and Canada approval in 2011. With this kind of drop past 2 days, I view it as a major opportunity to increase long positions for the quarter. I would want to be long going into the Q2 earnings call. I don't rule out either management change (would be a positive) or acquisition.